Cite

HARVARD Citation

    Yamamoto, Y. et al. (2022). Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS). Cancer science. 113 (9), pp. 3169-3179. [Online]. 
  
Back to record